Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The HER-2/ neu oncogene is a member of the erb B-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breast cancer cell lines. In the current study, alterations of the gene in 189 primary human breast cancers were investigated. HER-2/ neu was found to be amplified from 2- to greater than 20-fold in 30% of the tumors. Correlation of gene amplification with several disease parameters was evaluated. Amplification of the HER-2/ neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer. It retained its significance even when adjustments were made for other known prognostic factors. Moreover, HER-2/ neu amplification had greater prognostic value than most currently used prognostic factors, including hormonal-receptor status, in lymph node-positive disease. These data indicate that this gene may play a role in the biologic behavior and/or pathogenesis of human breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CNVs are involved in a large number of complex human diseases such as Down’s syndrome (trisomy 21) and many cancers, for example HER2 gene amplification in breast cancer (BC) (1–5).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [5]
In the citing paper
“In a seminal study, Slamon et al. found that HER2 is amplified in about 20% of breast cancers (Slamon et al., 1987).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Slamon et al., 1987
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene
Greenberg, M. E., & Ziff, E. B. (1984) · Nature · doi:10.1038/311433a0 · Cited by 3,064
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Self-citationClose similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationAmplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Self-citation
Research works printed but not linked: 1
- Maniatis, T., Molecular Cloning: A Laboratory Manual: 282 (1982).
Cited by
Items 201–300 of 1,056
Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., & Overgaard, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5565 · Cited by 568
Tissue Microarrays for Rapid Linking of Molecular Changes to Clinical Endpoints
Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Köchli, O. R., Mross, F., Dieterich, H., Moch, H., Mihatsch, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63075-1 · Cited by 566
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
Korkaya, H., Paulson, A., Iovino, F., & Wicha, M. S. (2008) · Oncogene · doi:10.1038/onc.2008.207 · Cited by 556
“The HER2 gene is amplified in 20–30% of human breast cancers and is associated with aggressive metastatic disease (Slamon et al., 1987; Slamon et al., 1989).”
BackgroundUntch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
Molecular Classification of Breast Cancer
Tsang, J. Y. S., & Tse, G. M. (2020) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000232 · Cited by 556
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 555
HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg, Å., Tandon, A., Sigurdsson, H., Clark, G. M., Fernö, M., Fuqua, S. A. W., Killander, D., & Wl, M. (1990) · PubMed · Cited by 554
Self-citationSeidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
“Approximately 20–30% of all breast cancers overexpress HER2 (Slamon et al, 1987; van de Vijver et al, 1988; Ross et al, 2003; Owens et al, 2004).”
BackgroundJunttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
“Gene amplification of HER2 defines the class and this alteration manifests itself in the overexpression of HER2 protein on the tumor cell surface in *20% of all primary breast cancers [2].”
BackgroundThe Distinctive Nature of HER2-Positive Breast Cancers
Burstein, H. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058197 · Cited by 541
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Korkaya, H., Kim, G.-I., Davis, A., Malik, F., Henry, N. L., Ithimakin, S., Quraishi, A. A., Tawakkol, N., D'Angelo, R., Paulson, A. K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.06.014 · Cited by 538
“The HER2 gene is amplified in approximately 20%–25% of human breast cancers, which are characterized by an aggressive clinical course (Slamon et al., 1987).”
BackgroundPerez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
“Trastuzumab was not permitted for patients whose post-AC (3-month) LVEF relative to their registration LVEF had either (1) decreased >15% points (absolute change), irrespective of whether the post AC LVEF fell above or below the institutional lower limit of normal (LLN), or decreased ≤15% points to a value below LLN.”
BackgroundSato, T., Tanigami, A., Yamakawa, K., Akiyama, F., Kasumi, F., Sakamoto, G., & Nakamura, Y. (1990) · PubMed · Cited by 536
Wen, Y., Hu, M. C. ‐., Makino, K., Spohn, B., Bartholomeusz, G. A., Yan, D., & Hung, M. (2000) · PubMed · Cited by 530
Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., & Rehemtulla, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030545097 · Cited by 530
Serra, V, Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodriguez, O., Guzman, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 528
“And third, HER2 overexpression/amplification is found in 20% in breast cancer patients (Slamon et al., 1987) and boosts PI3K signaling through HER2/HER3 heterodimerization (Holbro et al., 2003).”
BackgroundSeshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 526
Peles, E., Bacus, S. S., Koski, R. A., Lu, H. S., Wen, D., Ogden, S. G., Levy, R. B., & Yarden, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90131-u · Cited by 524
“An association between gene amplification and overexpression and clinical outcome has been reported in breast and ovarian cancers (Slamon et al., 1987; Varley et al., 1987; Venter et al., 1987; Zhou et al., 1987; Berger et al., 1988; Tsuda et al., 1989; Slamon et al., 1989).”
BackgroundExistent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., & Livingston, R. B. (1994) · PubMed · Cited by 524
Particle shape enhances specificity of antibody-displaying nanoparticles
Barua, S., Yoo, J.-W., Kolhar, P., Wakankar, A., Gokarn, Y. R., & Mitragotri, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216893110 · Cited by 523
“Here, we study the effect of shape using trastuzumab, a HER2 (human epidermal growth factor receptor 2)-targeting monoclonal antibody with proven therapeutic benefit (24) as a model antibody, polystyrene particles of two sizes (200 nm and 1 μm) and three shapes (spheres, rods, and disks) as model particles, and three…”
MethodSmart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
“A significant clinical correlation was shown between HER2/neu gene amplification and overexpression and parameters of malignancy, including reduced survival and reduced time to relapse, relative to patients with normal receptor levels (Slamon et al., 1987; Chazin et al., 1992).”
BackgroundSelf-citationBurstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll, R., Mitze, M., Frixen, U. H., & Birchmeier, W. (1993) · PubMed · Cited by 520
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
“HER2 overexpression is associated with a more aggressive disease, higher recurrence rate, and shortened survival [1–4].”
BackgroundThe Multifaceted Role of Curcumin in Cancer Prevention and Treatment
Shanmugam, M., Rane, G., Kanchi, M., Arfuso, F., Chinnathambi, A., Zayed, M., Alharbi, S., Tan, B., Kumar, A., & Sethi, G. (2015) · Molecules · doi:10.3390/molecules20022728 · Cited by 510
“HER2/neu is over-expressed in breast cancer [208], and both HER2 and EGF receptors stimulate proliferation of breast cancer cells.”
BackgroundPrognosis research strategy (PROGRESS) 4: Stratified medicine research
Hingorani, A. D., Windt, D. A. V. D., Riley, R. D., Abrams, K., Moons, K. G. M., Steyerberg, E. W., Schroter, S., Sauerbrei, W., Altman, D. G., Hemingway, H., et al. (2013) · BMJ · doi:10.1136/bmj.e5793 · Cited by 510
Sauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 509
Self-citationOncogenes and Tumor Suppressor Genes
Lee, E. Y. H. P., & Muller, W. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003236 · Cited by 508
Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., & Slamon, D. J. (2003) · PubMed · Cited by 507
Self-citationUntch, M., Fasching, P. A., Konecny, G. E., Hasmüller, S., Lebeau, A., Kreienberg, R., Camara, O., Müller, V., du Bois, A., Kühn, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4930 · Cited by 506
“Human epidermal growth factor receptor 2 (HER2) overexpression in breast cancer is associated with high risk of recurrence and metastasis.(1) Trastuzumab (Herceptin; Roche, Basel, Switzrerland), a monoclonal humanized antibody binding to the extracellular domain of HER2, is highly effective in the treatment of both me…”
BackgroundArcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0912 · Cited by 505
“Deregulation of the HER2 gene, through protein over-expression and/or gene amplification, is found in many human cancers most notably breast, ovarian, gastric and some biologically aggressive forms of uterine carcinomas (7-10).”
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
“org which translated into shorter disease-free interval and overall survival in patients with early and advanced disease (10).”
BackgroundDoi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30604-6 · Cited by 505
Nicolson, G. L. (1988) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046483 · Cited by 502
Rubin, I., & Yarden, Y. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s3 · Cited by 500
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan, Q., Kleer, C. G., van Golen, K. L., Irani, J., Bottema, K. M., Bias, C., Carvalho, M. D., Mesri, E. A., Robins, D. M., Dick, R. D., et al. (2002) · PubMed · Cited by 500
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
“The HER2 (ErbB2/neu) gene is amplified/overexpressed in 20% to 30% of invasive breast carcinomas with its overexpression being associated with increased metastatic potential and poor clinical outcome (1, 2).”
BackgroundDifferential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
“Moreover, analyses of clinical parameters show a correlation between both amplification and overexpression of HER2 and a worsened prognosis in that HER2-overexpressing patients have a shorter disease-free and overall survival period [20, 21, 50, 55 , 59, 66].”
BackgroundInfluentialSpector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Current and emerging biomarkers in breast cancer: prognosis and prediction
Weigel, M. T., & Dowsett, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0136 · Cited by 496
“Through the development of the monoclonal antibody trastuzumab, which is targeted at HER2, the amplification status of HER2 became also a highly predictive biomarker (Slamon et al. 1987, Mass et al. 2005).”
BackgroundAustin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 496
“In human breast cancer, the ErbB2 gene is amplified and overexpressed in 25% of cases and is associated with poor prognosis (Slamon et al., 1987).”
BackgroundNakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., & Nakano, H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-j · Cited by 494
“Breast carcinoma patients with overexpression of cerb B-2 have a significantly poorer survival rate than patients with low expression.(22,23,55) We also observed such a correlation between c-erb B-2 overexpression and gene amplification in intestinal type gastric carcinomas.”
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
The mammary gland iodide transporter is expressed during lactation and in breast cancer
Tazebay, U. H., Wapnir, I. L., Levy, O., Dohan, O., Zuckier, L. S., Hua Zhao, Q., Fu Deng, H., Amenta, P. S., Fineberg, S., Pestell, R. G., et al. (2000) · Nature Medicine · doi:10.1038/78630 · Cited by 493
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M. N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0913 · Cited by 492
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
“Trastuzumab is a humanized antibody that targets the transmembrane tyrosine kinase receptor, HER2 (a member of the EGFR family) that is commonly overexpressed in a quarter of all breast cancers [63].”
BackgroundTabernero, J., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., Song, C., Wu, H., Eng-Wong, J., Kim, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30481-9 · Cited by 490
A robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., Chenard, M.-P., Penault-Llorca, F., Nagelmeier, I., Schlake, W., et al. (2010) · Virchows Archiv · doi:10.1007/s00428-010-0952-2 · Cited by 486
“Monitoring of the tumor HER2 status (gene amplification and/or protein overexpression) in breast cancer has become routine as the positive HER2 status detected in around 25% of these cancers is associated with poorer prognosis, more aggressive disease, and an increased risk of disease recurrence [3–5].”
BackgroundSmolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
“Among these targets, human epidermal growth factor receptor II (HER-2), a member of the epidermal growth factor receptor family, is detected as overexpressed in 25% to 30% of all breast cancers (3).”
BackgroundRobert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1764 · Cited by 479
Self-citationMechanism of biological synergy between cellular Src and epidermal growth factor receptor
Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1415 · Cited by 472
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
“The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is overexpressed in approximately 15% of human breast cancers (Slamon et al., 1987).”
Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016140108 · Cited by 467
“HER2 is amplified in approximately 25% of human breast cancers (1) and is associated with poor prognosis (2).”
BackgroundErickson, S. L., O’Shea, K. S., Ghaboosi, N., Loverro, L., Frantz, G., Bauer, M., Lu, L. H., & Moore, M. W. (1997) · Development · doi:10.1242/dev.124.24.4999 · Cited by 467
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2025 · Cited by 467
“Approximately 25% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), and overexpression has been associated with worse disease-free and overall survivals.(1-4) The HER2positive phenotype correlates with poorly differentiated tumors, markers of high proliferative rate, and lack of expression…”
BackgroundMimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
p185neu expression in human lung adenocarcinomas predicts shortened survival.
Kern, J. A., Schwartz, D. A., Nordberg, J. E., Weiner, D. B., Greene, M. I., Torney, L., & Robinson, R. A. (1990) · PubMed · Cited by 466
Warner, E., Plewes, D. B., Shumak, R. S., Catzavelos, G. C., Di Prospero, L. S., Yaffe, M. J., Goel, V., Ramsay, E., Chart, P. L., Cole, D. E. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3524 · Cited by 461
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
“Introduction: Overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) occurs in approximately 15% of breast cancers and is associated with poor prognosis (1).”
Histological and molecular types of breast cancer: is there a unifying taxonomy?
Weigelt, B., & Reis-Filho, J. S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.166 · Cited by 457
Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1983 · Cited by 457
Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Self-citationLin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 456
β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis
Guo, W., Pylayeva, Y., Pepe, A., Yoshioka, T., Muller, W. J., Inghirami, G., & Giancotti, F. G. (2006) · Cell · doi:10.1016/j.cell.2006.05.047 · Cited by 455
Negishi, K., Negishi, T., Hare, J. L., Haluska, B. A., Plana, J. C., & Marwick, T. H. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.02.008 · Cited by 454
Whale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks203 · Cited by 453
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
“Despite the demonstration that the overexpression or activation of HER members plays an important role in breast cancer oncogenesis (Slamon et al., 1987), and that the activity of Akt was elevated in 40% of breast cancer patients (32 of 80 patient specimens) in a recent study (Sun et al., 2001),…”
BackgroundResultMolecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Allred, D. C., Clark, G. M., Molina, R., Tandon, A. K., Schnitt, S. J., Gilchrist, K. W., Osborne, C. K., Tormey, D. C., & McGuire, W. L. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90257-4 · Cited by 450
Self-citationERBB2 oncogene in human breast cancer and its clinical significance
Révillion, F., Bonneterre, J., & Peyrat, J. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10157-5 · Cited by 448
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
“Clinical studies established that Herceptin is active against HER-2-overexpressing MBC [1,2], leading to its approval in 1998 by the US Food and Drug Administration.”
BackgroundInfluentialHerbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
“and is associated with poor clinical outcome and disease progression [89, 90].”
BackgroundLoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
“In addition to EGFR (ERBB1), HER-2 (ERBB2) was first recognized over 20 years ago when it was found to be overexpressed in 30p of invasive breast cancers and shown to correlate inversely with time to tumor recurrence and overall survival (OS) [”
BackgroundSiegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
“Numerous studies estimate that erbB-2 is amplified and overexpressed in 20–30% of primary breast cancers, which correlates with poor patient prognosis (Slamon et al., 1987, 1989; Gullick et al., 1991; Paterson et al., 1991; Press et al., 1993; Andrulis et al., 1998).”
BackgroundA Novel Putative Tyrosine Kinase Receptor Encoded by the eph Gene
Hirai, H., Maru, Y., Hagiwara, K., Nishida, J., & Takaku, F. (1987) · Science · doi:10.1126/science.2825356 · Cited by 441
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1340 · Cited by 441
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
“The protein over-expression and gene amplification of HER2 occur in 13% to 20% of invasive ductal breast cancer, more than half of which (around 55%) are ER-PR- [66, 70, 71].”
BackgroundMundy, G. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1546::aid-cncr4>3.0.co;2-i · Cited by 440
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Knutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 438
Breast Cancer Metastasis to the Central Nervous System
Weil, R. J., Palmieri, D. C., Bronder, J. L., Stark, A. M., & Steeg, P. S. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61180-7 · Cited by 434
“It is overexpressed in 20 to 30% of breast carcinomas via gene amplification, and its overexpression correlates with poor patient survival.(9) Her-2 dimerizes with other members of the EGF receptor superfamily to initiate signaling that controls or influences multiple aspects of growth and differentiation.”
BackgroundHER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
“Importantly, mice that were null for the Fc gamma receptor expressed on natural killer cells, which are important for ADCC, lost much of the antitumor effect of trastuzumab, with only 29% tumor growth ADCC = antibody-dependent cellular cytotoxicity; ECD = extracellular domain; EGF = epidermal growth factor; EGFR = epi…”
BackgroundInfluentialOverexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M.-C. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 430
“Studies of individuals with ErbB2-overexpressing tumors have shown that they have a signi®cantly poor clinical outcome compared to patients whose tumors did not overexpress ErbB2 (Berchuck et al., 1990; Slamon et al., 1987, 1989).”
BackgroundInfluential
Metadata
- Authors
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L.
- Affiliations
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Genentech (US)
- Venue
- Science
- Published
- 1987-01-09
- Volume
- 235
- Issue
- 4785
- Pages
- 177-182
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141393790
- Cited by
- 11,760
- References
- 44
- Citations by year
- 2026: 209 · 2025: 230 · 2024: 301 · 2023: 309 · 2022: 302 · 2021: 346 · 2020: 336 · 2019: 325 · 2018: 344 · 2017: 395 · 2016: 416 · 2015: 433 · 2014: 486 · 2013: 549 · 2012: 459
- FWCI
- 103.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA36827, CA-30195)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- gene amplification, breast cancer, prognostic factors, relapse, overall survival, lymph node-positive disease, hormone receptor status, ErbB family, epidermal growth factor receptor
- MeSH terms
- Axilla, Breast Neoplasms, DNA, Female, Gene Amplification, Humans, Lymph Nodes, Neoplasm Recurrence, Local, Nucleic Acid Hybridization, Oncogenes, Prognosis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.